CD4 down-modulating compounds with potent anti-HIV activity

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Highly active antiretroviral therapy (HAART) has improved AIDS survival but faces challenges like drug resistance and side effects.
• Understanding HIV-1 entry, a complex process involving viral attachment, coreceptor interactions, and fusion, is key to developing new therapies.
• Enfuvirtide (T-20), a successful entry inhibitor, validates targeting HIV entry as a vital antiretroviral strategy.

Purpose of the Study:

• To review recent developments in therapeutic agents inhibiting HIV entry.
• To highlight novel compounds targeting the interaction between HIV envelope glycoprotein gp120 and the CD4 receptor.
• To focus on the anti-HIV activity and unique mechanism of cyclotriazadisulfonamides (CADA).

Main Methods:

• Review of recent scientific literature on HIV entry inhibitors.
• Analysis of therapeutic agents targeting gp120-CD4 binding.
• Examination of cyclotriazadisulfonamides (CADA) and their mechanism of action.

Main Results:

• Several agents inhibiting gp120-CD4 binding, including PRO 542, BMS-378806, TNX-355, PRO 2000, and CV-N, have been developed.
• Cyclotriazadisulfonamides (CADA) represent a novel class of compounds with significant anti-HIV activity.
• CADA function by down-modulating the CD4 receptor on lymphocytic and monocytic cells.

Conclusions:

• Targeting HIV entry is a promising strategy for developing new antiretroviral therapies.
• Novel entry inhibitors, such as CADA, offer unique mechanisms to combat HIV infection.
• Further development of entry inhibitors is encouraged by the success of agents like enfuvirtide and the potential of compounds like CADA.